Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptomsMichael J. Peluso, Timothy J. Henrich, Owen Janson et al.|Cell Reports|2021Cited by 266
Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological ManifestationsBing Sun, Lynn Pulliam, J. Daniel Kelly et al.|Cells|2021Cited by 187
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assayMichael J. Peluso, Bryan Greenhouse, Albert C. Shu et al.|Science Advances|2021Cited by 150
Drug–Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in miceSimon Döhrmann, Leslie W. Tari, James M. Balkovec et al.|Nature Microbiology|2025Cited by 13
CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidaseSimon Döhrmann, Leslie W. Tari, James M. Balkovec et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 0